Oxaprozin, sold under the brand name Daypro, is a nonsteroidal anti inflammatory drug (NSAID) prescribed for arthritis and other inflammatory pain. It is one of the few medications with a documented history of cross reacting on the benzodiazepine screening test, commonly called the BZO panel, on a urine drug test. This is not a hypothetical concern. A published comparison of three commercial benzodiazepine immunoassays found that oxaprozin, at concentrations consistent with normal therapeutic dosing, produced nonnegative results on all three platforms tested. This article explains what that means, why it happens, and how the laboratory confirmation and medical review officer (MRO) process is built specifically to sort a true benzodiazepine use from a medication cross reaction.
What the BZO screen actually measures
A benzodiazepine immunoassay does not identify a specific drug molecule by name. It uses antibodies designed to bind to a chemical structure shared across the benzodiazepine drug class, most often targeting metabolites such as oxazepam or nordiazepam at a federally set screening cutoff. Any molecule that resembles that target structure closely enough can bind the antibody and trigger a nonnegative, or "presumptive positive," screening result, even if it is not a benzodiazepine at all. This is called cross reactivity, and it is a known limitation of immunoassay technology that laboratories and regulators have accounted for by requiring a second, more specific test before any result is reported as a true positive.
Why oxaprozin specifically triggers a BZO cross reaction
Oxaprozin is chemically unrelated to the benzodiazepine drug class. It is a propionic acid derivative NSAID, in the same broad family as ibuprofen and naproxen, not a sedative. The cross reactivity on benzodiazepine immunoassays is a quirk of the antibody's binding behavior rather than any pharmacological overlap between the two drug classes. The drug label on file with the National Library of Medicine's DailyMed notes that oxaprozin has a long elimination half-life, and that a portion of a dose and its metabolites is excreted in urine, which is consistent with the drug being present at detectable levels in a urine specimen collected during ordinary once-daily dosing. The current oxaprozin prescribing information is available through DailyMed. The specific cross reactivity finding on benzodiazepine immunoassays, tested across three different commercial assay platforms, was published in the Journal of Analytical Toxicology and is indexed on PubMed. The study and its abstract can be reviewed on PubMed. No comparable, credible published evidence places oxaprozin on opiate, amphetamine, cocaine metabolite, cannabinoid (THC), or PCP immunoassays; the cross reaction described in the literature is specific to the benzodiazepine class screen.
How confirmation testing resolves the question
A screening immunoassay is a presumptive test. It is fast and inexpensive, but it is not drug specific. Any nonnegative screen on a regulated or laboratory based test is routed to confirmation testing using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS or LC/MS/MS). Confirmation testing identifies the exact molecule present, down to its specific chemical structure, rather than a family resemblance. Because oxaprozin is not a benzodiazepine and does not metabolize into oxazepam, nordiazepam, temazepam, or any other benzodiazepine analyte, a true oxaprozin related screening reaction is expected to resolve as negative on benzodiazepine confirmation while the oxaprozin itself can be separately identified if a laboratory specifically tests for it. This two step design, screen first and confirm second, is the reason a nonnegative immunoassay result is never, by itself, a confirmed drug finding.
The MRO process and prescription documentation
In any regulated or employer drug testing program that uses a medical review officer, a laboratory does not report a confirmed positive result to an employer until a licensed MRO has reviewed it. The medical review officer's role, defined under the federal workplace drug testing regulation at 49 CFR Part 40, is to contact the individual confidentially, ask about current prescriptions and legitimate medical explanations, and verify documentation before any result is reported as positive to the employer. The MRO verification process and employer reporting duties are set out in 49 CFR Part 40, Subpart G, on eCFR. An employee or applicant who takes oxaprozin, with or without a current prescription, should keep the pharmacy label or a note from the prescribing clinician available so the MRO can document it during that review. A screening reaction alone, even a well documented one like the oxaprozin and BZO interaction, is never a basis for a disciplinary or diagnostic conclusion on its own. This article is not medical advice, and an employee with questions about a specific medication should talk to the prescribing clinician or the reviewing MRO directly rather than changing or stopping a prescribed medication on their own.
NSAIDs and screening cross reactivity, for context
Oxaprozin is not the only NSAID with a cross reactivity history, though the strength and specificity of the evidence varies by drug and by assay generation. The table below summarizes what the published and labeling record supports for commonly discussed NSAIDs. Assay chemistry has changed over time, and a reaction reported with an older generation reagent does not necessarily occur with a current assay.
| NSAID | Screening panel discussed | What the evidence supports |
|---|---|---|
| Oxaprozin (Daypro) | Benzodiazepine (BZO) | Documented cross reactivity across three commercial immunoassay platforms in a published comparison; confirmation testing by GC/MS or LC/MS separates it from a true benzodiazepine finding. |
| Ibuprofen | THC (cannabinoid), occasionally PCP | Older generation immunoassay reagents were associated with reports of nonspecific reactions in some case literature; current assay chemistry has reduced this, and employers should treat any such result as presumptive and confirmation dependent rather than assume a mechanism. |
| Naproxen | THC, occasionally barbiturate panels | Similar to ibuprofen, reports are largely tied to older assay generations; limited current published evidence of reliable cross reactivity with modern immunoassays, and any nonnegative result still requires confirmation. |
For any NSAID other than oxaprozin on the benzodiazepine screen, the credible published evidence specific to that combination is limited; the safest statement an employer or a tested individual can rely on is that any screening result is presumptive until confirmed, and that the MRO review exists precisely to sort medication explanations from drug class findings.
What employers should keep in mind
A positive screening immunoassay is a trigger for the next step in the process, not a final result. Programs that follow the federal model, immunoassay screen, confirmation testing, and MRO review, are built to prevent exactly the situation an oxaprozin prescription could otherwise create. Employers operating under the Substance Abuse and Mental Health Services Administration's workplace testing framework should rely on certified laboratories and a qualified MRO rather than reading a screening result on its own. SAMHSA's workplace programs resources describe the certified laboratory and MRO structure used in federally regulated testing. Employers who are not covered by a federal testing mandate can still choose to build their program the same way, since the screen, confirm, and review sequence is the most reliable way to avoid acting on an unconfirmed result.
American Screening Corporation supplies the cups, dip cards, and oral fluid devices used for benzodiazepine and other panel screening, along with access to laboratory confirmation services; browse the drug test cup collection for panel configurations that include a BZO screen.
Related reading
- Does Naproxen Cause a False Positive Drug Test? NSAIDs, THC and Barbiturate Screens
- Does Valium Show Up on a Drug Test? Diazepam and the Benzodiazepine Panel
Frequently asked questions
Does oxaprozin cause a positive drug test for benzodiazepines?
It can cause a nonnegative screening result on a benzodiazepine (BZO) immunoassay. This has been documented in published testing across multiple commercial immunoassay platforms. A screening result is presumptive, not a confirmed finding.
What is a BZO screen?
BZO is the common laboratory abbreviation for the benzodiazepine screening immunoassay included on most urine drug test panels. It uses antibodies that target a chemical structure common to benzodiazepine metabolites, and it can occasionally react to unrelated molecules that happen to resemble that target closely enough.
Can lab confirmation tell the difference between oxaprozin and a real benzodiazepine?
Yes. Confirmation testing by GC/MS or LC/MS identifies the specific molecule present rather than a family resemblance. Oxaprozin does not metabolize into a benzodiazepine compound, so confirmation testing is the step that separates a true benzodiazepine finding from an oxaprozin related screening reaction.
What should an employee do if a screening test is positive but they only took oxaprozin?
Keep the pharmacy label or a note from the prescribing clinician available for the medical review officer. The MRO review process exists to collect that information confidentially before any result is reported to an employer as positive.
Does oxaprozin show up on a THC or opiate screen?
No credible published evidence links oxaprozin to cross reactivity on cannabinoid, opiate, amphetamine, or cocaine metabolite immunoassays. The documented reaction is specific to the benzodiazepine screen.
Should employers take disciplinary action based on a screening result alone?
No. A nonnegative immunoassay screen should always be confirmed and, where an MRO is used, reviewed for a legitimate medical explanation before any employment decision. Employers should generally consult legal counsel on how a confirmed result factors into a personnel decision.
This article is general information about drug test screening and confirmation science. It is not medical, legal, or employment advice. Anyone with questions about a specific medication, test result, or workplace policy should talk to a qualified clinician, a medical review officer, or legal counsel.
